Modeling MODS: What can be learned from animal models of the multiple-organ dysfunction syndrome?

Intensive Care Medicine

Volumn 31, Issue 5, 2005, Pages 605-608

  Marshall, John C ^a  

^a TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; ANTIBIOTIC AGENT; PENTOXIFYLLINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST;

ARTIFICIAL VENTILATION; BACTERIAL IMMUNITY; CRITICAL ILLNESS; DISEASE EXACERBATION; EDITORIAL; HEALTH INSURANCE; HOSPITAL INFECTION; HUMAN; INNATE IMMUNITY; INTENSIVE CARE UNIT; LUNG INJURY; MULTIPLE ORGAN FAILURE; NONHUMAN; PERITONITIS; RESUSCITATION; SEPSIS; SURVIVAL TIME; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

ANIMALS; BIOLOGICAL RESPONSE MODIFIERS; DISEASE MODELS, ANIMAL; MICE; MULTIPLE ORGAN FAILURE; PENTOXIFYLLINE; PPAR GAMMA; PROSTAGLANDIN D2; VASODILATOR AGENTS; ZYMOSAN;

EID: 18844454313     PISSN: 03424642     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00134-005-2595-3     Document Type: Editorial

References (17)

1. Skillman JJ, Bushnell LS, Goldman H, Silen W (1969) Respiratory failure, hypotension, sepsis, and jaundice. A clinical syndrome associated with lethal hemorrhage and acute stress ulceration in the stomach. Am J Surg 117:523-530
2. Baue AE (1975) Multiple, progressive, or sequential systems failure. A syndrome of the 1970s. Arch Surg 110:779-781
3. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RMH, Sibbald WJ (1992) ACCP/ SCCM consensus conference. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 101:1644-1655
4. Brower RG, Matthay MA, Morris A, Schoenfeld D, Thompson BT, Wheeler A, for the ARDS Network (2000) Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med 342:1301-1308
5. Hebert PC, Wells G, Blajchman MA, Marshall J, Martin C, Pagliarello G, Tweeddale M, Schweitzer I, Yetisir E, the Transfusion Requirements in Critical Care Investigators for the Canadian Critical Care Trials Group (1999) A multicentre randomized controlled clinical trial of transfusion requirements in critical care. N Engl J Med 340:409-417
6. Marshall JC (2001) Inflammation, coagulopathy, and the pathogenesis of the multiple organ dysfunction syndrome. Crit Care Med 29 [Suppl]:S106
7. 2 attenuates the development of zymosan-induced shock. Intensive Care Med (http://dx.doi.org/10.1007/s00134-005-2596-2)
8. Volman TJH, Goris RJA, Hendriks T (2005) Pentoxifylline does not improve outcome in a murine model for the multiple organ dysfunction syndrome. Intensive Care Med (http://dx.doi.org/ 10.1007/s00134-005-2570-z)
9. Steinberg S, Flynn W, Kelly K, Bitzer L, Sharma P, Gutierrez C, Baxter J, Lalka D, Sands A, Van Liew J, Hassett J, Price R, Beam T, Flint L (1989) Development of a bacteria independent model of the multple organ failure syndrome. Arch Surg 124:1390-1395
10. Schwieterman W, Roberts R (1997) FDA perspective on study design for therapies for severe sepsis. Sepsis 1:69
11. Piper RD, Cook DJ, Bone RC, Sibbald WJ (1996) Introducing critical appraisal to studies of animal models investigating novel therapies in sepsis. Crit Care Med 24:2059-2070
12. Villa P, Sartor G, Angelini M, Sironi M, Conni M, Gnocchi P, Isetta AM, Grau G, Buurman W, van Tits LJ, (1995) Pattern of cytokines and pharmacomodulation in sepsis induced by cecal ligation and puncture compared with that induced by endotoxin. Clin Diagn Lab Immunol 2:549-553
13. Yang S, Zhou M, Koo DJ, Chaudry IH, Wang P (1999) Pentoxifylline prevents the transition from the hyperdynamic to hypodynamic response during sepsis. Am J Physiol 277:H1036-H1044
14. Staubach KH, Schröder J, Stüber F, Gehrke K, Traumann E, Zabel P (1998) Effect of pentoxifylline in severe sepsis. Results of a randomized, double-blind, placebo-controlled study. Arch Surg 133:94-100
15. Shukla VK, Ojha AK, Pandey M, Pandey BL (2001) Pentoxifylline in perforated peritonitis: results of a randomised, placebo controlled trial. Eur J Surg 167:622-624
16. Marshall JC (2003) Such stuff as dreams are made on: mediator-targeted therapy in sepsis. Nat Rev Drug Disc 2:391-405
17. Marshall JC, Creery D (1998) Preclinical models of sepsis. Sepsis 2:187-197